Dr. Matthew Barnes
Claim this profileGastroenterology Associates, PA
Studies Ulcerative Colitis
Studies Colitis
7 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Matthew Barnes is currently running
TAK-279
for Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting0 awards Phase 21 criteria
TAK-279
for Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.
Recruiting0 awards Phase 2
More about Matthew Barnes
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Matthew Barnes has experience with
- ABX464
- TAK-279
- Mirikizumab
- TAK-101
- Vedolizumab
- Upadacitinib
Breakdown of trials Matthew Barnes has run
Ulcerative Colitis
Colitis
Celiac Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Barnes specialize in?
Matthew Barnes focuses on Ulcerative Colitis and Colitis. In particular, much of their work with Ulcerative Colitis has involved treating patients, or patients who are undergoing treatment.
Is Matthew Barnes currently recruiting for clinical trials?
Yes, Matthew Barnes is currently recruiting for 3 clinical trials in Greenville South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Matthew Barnes has studied deeply?
Yes, Matthew Barnes has studied treatments such as ABX464, TAK-279, Mirikizumab.
What is the best way to schedule an appointment with Matthew Barnes?
Apply for one of the trials that Matthew Barnes is conducting.
What is the office address of Matthew Barnes?
The office of Matthew Barnes is located at: Gastroenterology Associates, PA, Greenville, South Carolina 29607 United States. This is the address for their practice at the Gastroenterology Associates, PA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.